Cargando…
Betulinic Acid-Mediated Tuning of PERK/CHOP Signaling by Sp1 Inhibition as a Novel Therapeutic Strategy for Glioblastoma
Patients with glioblastoma are at high risk of local recurrences after initial treatment with standard therapy, and recurrent tumor cells appear to be resistant to first-line drug temozolomide. Thus, finding an effective second-line agent for treating primary and recurrent glioblastomas is critical....
Autores principales: | Lo, Wei-Lun, Hsu, Tsung-I, Yang, Wen-Bin, Kao, Tzu-Jen, Wu, Ming-Hsiao, Huang, Yung-Ning, Yeh, Shiu-Hwa, Chuang, Jian-Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226172/ https://www.ncbi.nlm.nih.gov/pubmed/32326583 http://dx.doi.org/10.3390/cancers12040981 |
Ejemplares similares
-
Fine‐tuning PERK signaling for neuroprotection
por: Halliday, Mark, et al.
Publicado: (2017) -
Sinulariolide Induced Hepatocellular Carcinoma Apoptosis through Activation of Mitochondrial-Related Apoptotic and PERK/eIF2α/ATF4/CHOP Pathway
por: Chen, Yi-Jen, et al.
Publicado: (2013) -
Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma
por: Li, Yong, et al.
Publicado: (2022) -
CNPY2 is a Key Initiator of the PERK-CHOP Pathway of the Unfolded Protein Response
por: Hong, Feng, et al.
Publicado: (2017) -
7-Acetylsinumaximol B Induces Apoptosis and Autophagy in Human Gastric Carcinoma Cells through Mitochondria Dysfunction and Activation of the PERK/eIF2α/ATF4/CHOP Signaling Pathway
por: Tsai, Tsung-Chang, et al.
Publicado: (2018)